An observational study to follow clinical outcomes for the patients participated in the randomized, phase III trial of sequential capecitabine/5FU plus bevacizumab (Cape/5FU-Bmab) to capecitabine/5FU plus oxaliplatin plus bevacizumab (CapeOX/mFOLOFX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer

C" Study - C" Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036690

Enrollment

311

Registered

2019-05-10

Start date

2019-06-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients wwho paticipated in the C- cubed study/

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Final update of OS in C-cubed study. Determination of patient population to RAS/BRAF mutations.	—

Secondary

Measure	Time frame
Among the participating patients in C-cubed Study, we are planing to collect tumor tissues and analyze cancer-related genetic, epigenetic and immunological altelations by using DNA/RNA and IHC.	—

Countries

Japan

Contacts

Public ContactTakeshi Nagasaka

Kawasaki Medical School Department of Clinical Oncology

takeshin@med.kawasaki-m.ac.jp0864621111

Outcome results